Strata Skin Sciences Q4 rev $8.7M, net loss $3.8M; FY rev $33.4M, net loss $10.8M

STRATA Skin Sciences, Inc.

Q4 2023 revenue $8.7M vs $10.6M in Q4 2022; net loss $3.8M ($0.11 EPS) vs $0.2M loss.
Full-year 2023 revenue $33.4M vs $36.2M; net loss $10.8M ($0.31 EPS) vs $5.6M loss.
Recorded $2.3M goodwill impairment in dermatology recurring procedures segment.
Installed XTRAC base 923 devices; launched TheraClear X acne system with 92 devices in operation.
Dr. Dolev Rafaeli appointed Vice-Chairman, President and CEO in October 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.